On November 11, the closing limit pool, now this pharmaceutical stock!

According to data from the Oriental Wealth Network Market Information Center, the stocks in the limit pool on November 11 mainly came from the Web 3.
0, tourism, medicine and other sectors
.
Among them, the stocks in the pharmaceutical sector include Longjin Pharmaceutical
.
Longjin Pharmaceutical closed on November 11, up 10.
01%, and closed at 16.
16 yuan
.
The stock opened the limit 6 times on the 11th, sealing the limit for 13 minutes and 14 seconds
.
Industry analysts believe that the reason for the stock is traditional Chinese medicine + industrial hemp + generic drugs
.
First of all, the company has been engaged in the research and development, production and sales of modern proprietary Chinese medicine and high-end chemical generic drugs, the main product is Longjin injection lamp anthocyanin, the product is listed in the "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2009 Edition)", and after 2010 has successively become Yunnan and other provinces and cities "National Essential Drugs List" (2009 edition) local supplementary varieties, the product has the effect of activating blood circulation and removing stasis, channeling and relieving pain, mainly used for the treatment of stroke and its sequelae, coronary heart disease, angina
。 In recent years, the aging of the population has intensified, consumption has been continuously upgraded, and the industry expects that cardiovascular and cerebrovascular proprietary Chinese medicines will gradually grow
in hospital terminal applications.
The concept of industrial hemp is hot this year, mainly because the United States promotes the full legalization of hemp to open up the huge market demand
for industrial hemp.
Guoyuan Securities once believed that policy legalization is the main driving force
for the development of the cannabis industry.
In particular, the United States has begun to experiment with the legalization of cannabis at the federal level, and if successful, it is expected to open up a huge market
in the United States.
Overseas mature markets will add CBD-based cannabinoids to more application scenarios
.
Under the neutral scenario, the global cannabis industry market size is expected to increase to $58.
7 billion by 2024.

Longjin Pharmaceutical once said on the interactive platform that the main body of the company's industrial hemp business is Yunnan Muya Agricultural Technology Co.
, Ltd.
, a holding subsidiary.

It is reported that the company has increased its capital in Yunnan Muya Agricultural Technology Co.
, Ltd.
(Muya Agriculture) by 15 million yuan and obtained 51% of its equity
.
Muya Agriculture's main business is large-scale cultivation of industrial hemp
.
In addition, with the promotion of policies such as consistency evaluation and normalization of centralized procurement, the profits of generic drugs are small, forcing pharmaceutical companies to accelerate the transformation
to high-end generic drugs and innovative drugs.
Longjin Pharmaceutical announced in June this year that its indirect holding subsidiary Longjin Kangyou, wholly-owned subsidiary Longjin Brahma and natural person Ji Yanfeng invested in the establishment of "Yunnan Longjin Kangrun Biopharmaceutical Co.
, Ltd
.
" with a registered capital of RMB 50 million.
It is reported that Yunnan Longjin Kangrun Biopharmaceutical Co.
, Ltd.
will be used as a high-end chemical generic drug development platform
.
From the perspective of the capital flow of individual stocks on November 11, Longjin Pharmaceutical's net inflow of manpower was 137 million yuan, and the net inflow of the main capital in the past 5 days was 379 million yuan
.
The company's third quarterly report in 2022 shows that the company's total operating income during the reporting period was 103 million yuan, down 82.
7% year-on-year; The net profit attributable to the parent was -3.
32 million yuan, compared with 6.
573 million yuan in the same period of the previous year, failing to maintain profitability
.
As for the reason for the sharp decline in revenue, the company said that it mainly transferred the equity of its subsidiary Yunnan Longjin Pharmaceutical Sales Co.
, Ltd.
in October 2021, so the operating income in the current period fell significantly
.
Due to the continuous impact of adverse factors such as policies such as medical insurance payment and repeated regional epidemics, the sales volume of the company's main products decreased year-on-year, and the main revenue of the parent company decreased
year-on-year.
The loss of net profit attributable to the parent was due to the continuous impact of policies such as medical insurance payment and hospital prescription restrictions and unfavorable factors such as the regional epidemic, the company's operating income declined, and the company's chemical class 1 new drugs and chemical generic drugs increased according to the progress of the project, and income tax expense increased
.
Net profit decreased
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.